Literature DB >> 20345925

Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Amandeep Mann1, Rachel F Tyndale.   

Abstract

Cytochrome P450 (CYP) 2D6 is an enzyme that is expressed in liver and brain. It can inactivate neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1,2,3,4-tetrahydroisoquinoline and beta-carbolines. Genetically slow CYP2D6 metabolizers are at higher risk for developing Parkinson's disease, a risk that increases with exposure to pesticides. The goal of this study was to investigate the neuroprotective role of CYP2D6 in an in-vitro neurotoxicity model. SH-SY5Y human neuroblastoma cells express CYP2D6 as determined by western blotting, immunocytochemistry and enzymatic activity. CYP2D6 metabolized 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin and the CYP2D6-specific inhibitor quinidine (1 microM) blocked 96 +/- 1% of this metabolism, indicating that CYP2D6 is functional in this cell line. Treatment of cells with CYP2D6 inhibitors (quinidine, propanolol, metoprolol or timolol) at varying concentrations significantly increased the neurotoxicity caused by 1-methyl-4-phenylpyridinium (MPP+) at 10 and 25 microM by between 9 +/- 1 and 22 +/- 5% (P < 0.01). We found that CYP3A is also expressed in SH-SY5Y cells and inhibiting CYP3A with ketoconazole significantly increased the cell death caused by 10 and 25 microM of MPP+ by between 8 +/- 1 and 30 +/- 3% (P < 0.001). Inhibiting both CYP2D6 and CYP3A showed an additive effect on MPP+ neurotoxicity. These data further support a possible role for CYP2D6 in neuroprotection from Parkinson's disease-causing neurotoxins, especially in the human brain where expression of CYP2D6 is high in some regions (e.g. substantia nigra).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345925      PMCID: PMC5262472          DOI: 10.1111/j.1460-9568.2010.07142.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  55 in total

1.  How human neuroblastoma cells make morphine.

Authors:  Chotima Boettcher; Monika Fellermeier; Christian Boettcher; Birgit Dräger; Meinhart H Zenk
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

2.  Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase.

Authors:  P M Watts; A G Riedl; D C Douek; R J Edwards; A R Boobis; P Jenner; C D Marsden
Journal:  Neuroscience       Date:  1998-09       Impact factor: 3.590

3.  In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos.

Authors:  Jun Tang; Yan Cao; Randy L Rose; Ernest Hodgson
Journal:  Chem Biol Interact       Date:  2002-10-20       Impact factor: 5.192

4.  Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.

Authors:  Ai-Ming Yu; Jeffrey R Idle; Kristopher W Krausz; Adrian Küpfer; Frank J Gonzalez
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

5.  Endogenous formation of morphine in human cells.

Authors:  Chotima Poeaknapo; Jürgen Schmidt; Matthias Brandsch; Birgit Dräger; Meinhart H Zenk
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

6.  Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function.

Authors:  Fabien Dutheil; Sandrine Dauchy; Monique Diry; Véronique Sazdovitch; Olivier Cloarec; Lucille Mellottée; Ivan Bièche; Magnus Ingelman-Sundberg; Jean-Pierre Flinois; Isabelle de Waziers; Philippe Beaune; Xavier Declèves; Charles Duyckaerts; Marie-Anne Loriot
Journal:  Drug Metab Dispos       Date:  2009-04-09       Impact factor: 3.922

7.  Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells.

Authors:  Catherine R McMillan; Rohita Sharma; Tom Ottenhof; Lennard P Niles
Journal:  Neurosci Lett       Date:  2007-04-19       Impact factor: 3.046

8.  The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study.

Authors:  Ewa Bromek; Anna Haduch; Władysława A Daniel
Journal:  Eur J Pharmacol       Date:  2009-10-08       Impact factor: 4.432

9.  MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

Authors:  R Fonne-Pfister; M J Bargetzi; U A Meyer
Journal:  Biochem Biophys Res Commun       Date:  1987-11-13       Impact factor: 3.575

10.  Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course.

Authors:  Jiang Yue; Sharon Miksys; Ewa Hoffmann; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2008-01       Impact factor: 6.186

View more
  17 in total

1.  MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex.

Authors:  Giulia Costa; Nicola Simola; Micaela Morelli
Journal:  Psychopharmacology (Berl)       Date:  2014-04-01       Impact factor: 4.530

2.  Sex hormones regulate cerebral drug metabolism via brain miRNAs: down-regulation of brain CYP2D by androgens reduces the analgesic effects of tramadol.

Authors:  Jie Li; Mengmeng Xie; Xiaoshuang Wang; Xiufang Ouyang; Yu Wan; Guicheng Dong; Zheqiong Yang; Jing Yang; Jiang Yue
Journal:  Br J Pharmacol       Date:  2015-08-26       Impact factor: 8.739

3.  CYP3A genes and the association between prenatal methylmercury exposure and neurodevelopment.

Authors:  Sabrina Llop; Van Tran; Ferran Ballester; Fabio Barbone; Aikaterini Sofianou-Katsoulis; Jordi Sunyer; Karin Engström; Ayman Alhamdow; Tanzy M Love; Gene E Watson; Mariona Bustamante; Mario Murcia; Carmen Iñiguez; Conrad F Shamlaye; Valentina Rosolen; Marika Mariuz; Milena Horvat; Janja S Tratnik; Darja Mazej; Edwin van Wijngaarden; Philip W Davidson; Gary J Myers; Matthew D Rand; Karin Broberg
Journal:  Environ Int       Date:  2017-05-10       Impact factor: 9.621

Review 4.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

Review 5.  Use of magnetic resonance imaging in pharmacogenomics.

Authors:  Roberto Viviani; Marie-Louise Lehmann; Julia C Stingl
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

6.  Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys.

Authors:  R T Miller; S Miksys; E Hoffmann; R F Tyndale
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 7.  Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.

Authors:  Mohd Sami Ur Rasheed; Abhishek Kumar Mishra; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2017-09-04       Impact factor: 3.996

Review 8.  Cytochrome P450 enzymes in the brain: emerging evidence of biological significance.

Authors:  Charmaine S Ferguson; Rachel F Tyndale
Journal:  Trends Pharmacol Sci       Date:  2011-10-03       Impact factor: 14.819

9.  Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects.

Authors:  Jibran Y Khokhar; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2010-11-24       Impact factor: 7.853

10.  Cytotoxic Effects of 3,4-Catechol-PV (One Major MDPV Metabolite) on Human Dopaminergic SH-SY5Y Cells.

Authors:  Teresa Coccini; Sarah Vecchio; Marta Crevani; Uliana De Simone
Journal:  Neurotox Res       Date:  2018-06-22       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.